Pro Medicus And 2 Other High Growth Tech Stocks In Australia
In the current Australian market landscape, the ASX 200 futures are indicating a slight dip of -0.2% amid geopolitical tensions and mixed economic signals, while unemployment remains stable at 4.1%. Against this backdrop, high growth tech stocks like Pro Medicus are garnering attention for their potential to thrive in uncertain conditions by leveraging innovation and adaptability to navigate market challenges.
Name
Revenue Growth
Earnings Growth
Growth Rating
Gratifii
42.14%
113.99%
★★★★★★
Pro Medicus
22.19%
23.49%
★★★★★★
WiseTech Global
20.15%
25.52%
★★★★★★
Wrkr
56.40%
116.83%
★★★★★★
AVA Risk Group
29.15%
108.15%
★★★★★★
Echo IQ
61.50%
65.86%
★★★★★★
BlinkLab
65.54%
64.35%
★★★★★★
Immutep
70.42%
42.39%
★★★★★☆
Adveritas
52.34%
88.83%
★★★★★★
SiteMinder
19.89%
69.58%
★★★★★☆
Click here to see the full list of 47 stocks from our ASX High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$28.92 billion.
Operations: Pro Medicus Limited generates revenue primarily through the production of integrated software applications for the healthcare industry, totaling A$184.58 million. The company's operations span Australia, North America, and Europe, focusing on imaging software and radiology information systems for medical facilities.
Pro Medicus, a standout in the Australian tech landscape, exemplifies robust growth with its revenue and earnings forecast to expand at 22.2% and 23.5% per annum respectively, significantly outpacing the broader market's expectations. This performance is bolstered by strategic share repurchases, with a recent buyback of 28,326 shares for AUD 6.35 million enhancing shareholder value. Additionally, inclusion in the S&P International 700 and Global 1200 indices not only underscores its market relevance but also augments its visibility among global investors. The company's commitment to innovation is evident from its R&D initiatives aimed at advancing healthcare technology solutions—a sector witnessing rapid growth due to increasing demand for efficient medical services.
Navigate through the intricacies of Pro Medicus with our comprehensive health report here.
Explore historical data to track Pro Medicus' performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: SEEK Limited operates as an online employment marketplace service provider across Australia, South East Asia, New Zealand, the United Kingdom, Europe, and other international markets with a market cap of A$8.55 billion.
Operations: The company generates revenue primarily through its employment marketplace services, with A$821.40 million from the ANZ region and A$240.90 million from Asia.
Amidst a challenging landscape, SEEK has demonstrated resilience with its revenue and earnings poised for significant growth. Despite a substantial one-off loss of A$119.8 million last year, the company's revenue is expected to rise by 9.1% annually, outpacing the Australian market's growth of 5.6%. Furthermore, SEEK's earnings are forecasted to surge by 25.9% per year, notably higher than the market average of 11.6%. This robust financial outlook is underpinned by strategic initiatives and an Analyst/Investor Day that highlighted future prospects, reinforcing SEEK's potential in a competitive sector.
Unlock comprehensive insights into our analysis of SEEK stock in this health report.
Understand SEEK's track record by examining our Past report.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases, with a market cap of A$8.43 billion.
Operations: Telix Pharmaceuticals generates revenue primarily from its Precision Medicine segment, which accounts for A$771.11 million, while its Therapeutics and Manufacturing Solutions segments contribute A$9.35 million and A$2.75 million, respectively.
Telix Pharmaceuticals has demonstrated a robust trajectory in the high-growth tech sector, particularly through its innovative approaches in prostate cancer imaging. With a staggering annual earnings growth of 858% last year and an expected annual revenue increase of 19.8%, Telix outpaces the Australian market's average growth significantly. Recent strategic product launches, like the AlFluor™ platform and Illuccix®, have not only expanded its portfolio but also fortified its market position by enhancing diagnostic precision and treatment efficacy in oncology. These developments underscore Telix's commitment to advancing healthcare technology, positioning it well for sustained growth amidst evolving medical demands.
Delve into the full analysis health report here for a deeper understanding of Telix Pharmaceuticals.
Gain insights into Telix Pharmaceuticals' past trends and performance with our Past report.
Click here to access our complete index of 47 ASX High Growth Tech and AI Stocks.
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:PME ASX:SEK and ASX:TLX.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Sequa Petroleum N.V. Update
LONDON, June 23, 2025--(BUSINESS WIRE)--Regulatory News: (BOURSE:MLSEQ) Further to its announcement of 19 May 2025, Sequa Petroleum N.V. (the "Company") has continued to monitor the situation and has not received any indication that progress towards completion of the Transaction will restart. Despite extensive efforts the Company has not been able to raise new equity capital, and without completion of the Transaction the Company will not be able to maintain a going concern nor pursue its business development strategy. Accordingly, the Company has started to reduce its remaining financial liabilities as required to pursue closure of the Company in compliance with statutory provisions for dissolution of the Company and its subsidiaries, and in a solvent manner. The Company is preparing for an extraordinary general meeting of shareholders to be held in the near term to resolve on the dissolution process. View source version on Contacts info@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Steadfast Group Limited (ASX:SDF) is favoured by institutional owners who hold 55% of the company
Significantly high institutional ownership implies Steadfast Group's stock price is sensitive to their trading actions 51% of the business is held by the top 11 shareholders Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Steadfast Group Limited (ASX:SDF) should be aware of the most powerful shareholder groups. With 55% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's take a closer look to see what the different types of shareholders can tell us about Steadfast Group. See our latest analysis for Steadfast Group Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Steadfast Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Steadfast Group's historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Steadfast Group is not owned by hedge funds. The company's largest shareholder is Australian Super Pty Ltd, with ownership of 9.7%. The second and third largest shareholders are First Sentier Investors (Australia) IM Ltd and Colonial First State Investments Limited, with an equal amount of shares to their name at 6.3%. A closer look at our ownership figures suggests that the top 11 shareholders have a combined ownership of 51% implying that no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Shareholders would probably be interested to learn that insiders own shares in Steadfast Group Limited. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around AU$317m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling. With a 36% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Steadfast Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. We can see that Private Companies own 3.7%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. It's always worth thinking about the different groups who own shares in a company. But to understand Steadfast Group better, we need to consider many other factors. To that end, you should be aware of the 3 warning signs we've spotted with Steadfast Group . But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
5 Timely Ideas To Improve Medicare Advantage
WASHINGTON, DC - MARCH 14: Dr. Mehmet Oz, arrives for his confirmation hearing with the Senate ... More Finance Committee in the Dirksen Senate Office Building on March 14, 2025 in Washington, DC. Oz is U.S. President Donald Trump's nominee to be administrator of the Centers for Medicare and Medicaid Services. (Photo by) In April, Dr. Mehmet Oz became Administrator of the Centers for Medicare & Medicaid Services (CMS). While his appointment generated a buzz, it is the work ahead that truly matters, especially when it comes to Medicare Advantage (MA), the program that provides care to about 33 million people, or 54 percent of the Medicare population. Though MA is poised to provide the best outcomes for the most Americans, the program is also ripe for reform, and there are several critical areas Oz could focus on to drive meaningful improvement. Here are five: 1. Pilot Multiyear Enrollment in Plans. MA plans looking to make investments in prevention and effective treatment face a conundrum: people under our care drop out of our plans on an annual basis. One way to fix this is to move away from annual enrollment and create options for people to enroll in plans for several years at a time. Dr. Oz has called for 'shifting the paradigm for health care from a system that focuses on sick care to one that fosters prevention, wellness, and chronic disease management.' Multiyear enrollment would provide the necessary incentives to achieve this worthy goal because you can't really invest in improving health in 1-year increments. 2. Standardize Plan Benefits. Plans should be competing based on excellence and their proven abilities to drive outcomes, not edge benefits and giveaways like cash rebates. By adopting standardized plan benefits and requiring them to address genuine health needs, CMS could ensure that when consumers choose plans on the basis of plan quality and health outcomes—which should be the most important metric in their decision-making process. 3. Reform Broker Commissions. Lately, there's been a lot of talk about reforming the way MA brokers are compensated. Last year, CMS issued a rule capping broker compensation, but that rule was blocked by a judge before it took effect. And recently, the Department of Justice alleged in a lawsuit that insurers were paying kickbacks to brokers in return for steering beneficiaries toward their plans. Amid these developments, we too rarely discuss ways to encourage brokers to steer people toward higher-quality plans. It's time to align broker commissions with plan ratings. Under this approach, a broker who enrolls a client in a higher-rated plan would receive a larger commission than one who steers a client toward a lower-rated plan. CMS estimates that last year almost 38% of MA enrollment was in plans with fewer than four stars. We owe it to plan members to create a system that provides their brokers with every incentive to help them choose plans of the highest quality. 4. Reform the Broker Industry to Focus More on Clinical Support. While we'refocusing on brokers, let's also provide them with incentives to use their expertise more expansively to improve health. I've spoken to brokers who help clients find care and navigate medical bureaucracies, locate the best prices on medications, and even connect them with life-saving social services. Brokers earn renewal fees when their clients sign up annually for MA plans. Those renewal fees should be earned by annually providing clients with care navigation and other health services that drive positive clinical outcomes. Brokers who don't offer such services should receive reduced renewal fees—or maybe not continue to serve seniors at all. Either way, it's worth noting how many outstanding brokers already do this work and are among the most trusted members of their communities—exactly the kind of behaviors that should be rewarded. 5. Incentivize Integration Between Health Plans and Provider Organizations. There's a lot of friction in our healthcare system, especially between health plans and provider organizations. Plans allege providers drive up costs with unnecessary procedures, tests and prescription medications; providers say plans are inflexible and stand in the way of appropriate patient care. It's beyond time to change the dynamic between these two groups. Many have already discovered that the best way to do this is to enter into global capitation arrangements by which providers receive a fee to manage all of a plan member's healthcare expenses. The benefit of these arrangements is that they encourage each group to focus on what they do best: payers manage risk while providers make decisions about direct care. The best of these arrangements are true partnerships in which payers and providers transparently design products together that play to both groups' strengths with an orientation toward improving outcomes. Going forward, it would be in patients' interests for CMS to offer a standardized framework for payers and providers to collaborate in this way. The appointment of a new CMS Administrator presents a unique opportunity to enact substantial and lasting changes. That's certainly the case with Dr. Mehmet Oz. By focusing on these five key areas, he can help unleash the full potential of Medicare Advantage, benefiting older adults across the country.
